Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...
Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...
Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...
Novo Nordisk expects its GLP-1 drugs Wegovy and Ozempic to soon come off the Food and Drug Administration’s official shortage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results